Risk factors for trastuzumab cardiotoxicity
Click here for a preview
Trastuzumab cardiotoxicity: Trastuzumab is a monoclonal antibody targeting the HER2 (human epidermal growth factor receptor 2) used in the treatment of HER2 positive breast cancer. The drug when used in the treatment of early stage breast cancer, reduces recurrences by half and mortality by one third. But trastuzumab trials have shown severe heart failure or cardiac event rate up to 3.9%.
Important risk factors for cardiotoxicity with trastuzumab treatment are:
- Age above 50 years
- Underlying heart disease or hypertension
- Baseline left ventricular ejection fraction 50-55% or lower
- Previous anthracycline therapy
- Laxmi S. Mehta, Karol E. Watson, Ana Barac, Theresa M. Beckie, Vera Bittner, Salvador Cruz-Flores, Susan Dent, Lavanya Kondapalli, Bonnie Ky, Tochukwu Okwuosa, Ileana L. Piña, Annabelle Santos Volgman and On behalf of the American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018;137:e30-e66.
||MCQs in Medicine - Cardiovascular System is based on undergraduate medical curriculum. Though the questions are aimed at basic post graduate entrance examinations, candidates taking competitive exams at the post graduate exit level may also find them useful, especially the explanations for the answers. Undergraduate medical students will find them useful for answering MCQ tests in their regular exams. More than just answering MCQs, the explanations will improve the knowledge and understanding about the conditions discussed.Medicine MCQs - Cardiovascular System Kindle Edition: Click Here for a Preview
Comments and suggestions are most welcome.